Abbott India Gears Up for Q3 Reveal on 12th February; Check Key Expectations Here

Abbott India Q3 results FY26 are scheduled to be announced on 12th February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Abbott India Q3 Results 2026 Preview

• Abbott India revenue is expected to be in the range of ₹1,614.28 crore, a 1.13% YoY decrease. 
• Profit After Tax, or PAT, is projected to rise 0.61% YoY. 
• Net profit is ₹360.78 crore, a rise 0.61% YoY 
• EBITDA to fall 0.79%

Abbott India Share Performance 

• Over the past six months, Abbott India's share price has fallen by 17.71% to ₹17,135.
• Moreover, over the past year, the stock has decreased by 6.85%.
• Despite this weak short-term performance, Abbott India's stock has delivered a financially sound 87.93% return over the past 5 years.
• As of 11th February 2026, the stock traded at ₹27,135.00 per share.

About Abbott India

Abbott India is one of the oldest and most respected healthcare companies in India, operating as the Indian subsidiary of the global healthcare giant Abbott Laboratories. Headquartered in Mumbai, the company has been serving the Indian market since 1910, offering a wide range of products across pharmaceuticals, nutrition, medical devices, and diagnostics. Abbott India’s portfolio includes trusted branded generic medicines, infant and adult nutrition products, diagnostic solutions, and chronic disease management devices, catering to both urban and rural healthcare needs.

Key Factors to Watch for Abbott India Q3 Results FY26

• Revenue Growth: Monitor YoY and QoQ sales performance across pharmaceuticals, nutrition, devices, and diagnostics.
  
• Profitability & Margins: Check operating margins (EBITDA) and net profit trends amid cost pressures.
  
• Earnings Per Share (EPS): Compare EPS growth versus prior quarters and year‑ago period.
  
• Segment Performance: Pharmaceuticals (chronic therapies), nutrition, devices, and diagnostics performance will be key.
  
• Cost & Expense Trends: Evaluate SG&A, R&D, and input costs impacting overall margins.
  
• Management Guidance: Outlook on FY26 growth, pricing, regulatory impact, and investments.
  
• Market & Peer Comparison: Assess performance relative to other pharma companies reporting Q3 results.

Final Thoughts

Abbott India will announce its Q3 FY26 results on 12th February 2026. Analysts expect 1.13% revenue growth, a 0.61% rise in PAT, and a 0.79% fall in EBITDA. Abbott India focuses on revenue growth, margins, EPS, segment performance, and management guidance for FY26. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Recent Articles

GOCL Corporation Q3 Results FY26 Preview

Godrej Industries Q3 Results FY26 Preview

Godawari Power and Ispat Q3 Results FY26 Preview

Hikal Q3 Results FY26 Preview

Himatsingka Seide Q3 Results FY26 Preview

Igarashi Motors India FY26 Preview

IG Petrochemicals Ltd Q3 Results FY26 Preview

IOL Chemicals & Pharmaceuticals Q3 Results FY26 Preview